How to succeed in the business of biotech patentability

The US Supreme Court has thrown down the gauntlet for patent eligibility in the biotechnology field. In spite of (or due to) their significant contributions to medicine, Mayo v Prometheus, Association for Molecular Pathology v Myriad Genetics, and Ariosa Diagnostics v Sequenom exemplify the harsh reality of recent changes in defining patent-eligible subject matter. These recent changes have left companies wondering how best to protect their products.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

12 March 2026 The event unpacked how technology, litigation trends, and global events are adding complexity while also offering benefits for legal teams under pressure to reduce costs.

Americas

Astellas blocks generic version of key urology drug until 2030

12 March 2026 The pharma company has successfully enforced its patents against Ascent’s proposed mirabegron copy, shortly after inking licensing deals elsewhere over the medication.

Americas

Medtech Magnolia fails to revive $2.1m verdict at Fed Circ

9 March 2026 Appeals court upholds lower court’s ruling, clarifying key legal questions concerning patent claims for blood‑testing devices.